Cite
HARVARD Citation
Conte, P. et al. (2020). Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer. Cancer. 126 (13), pp. 3132-3139. [Online].